Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
INBS 
Intelligent Bio Solutions Inc. (INBS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
10/31/2025: INBS (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $12
1 Year Target Price $12
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -82.27% | Avg. Invested days 20 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/31/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 8.86M USD | Price to earnings Ratio - | 1Y Target Price 12 |
Price to earnings Ratio - | 1Y Target Price 12 | ||
Volume (30-day avg) 1 | Beta 4.49 | 52 Weeks Range 0.92 - 2.75 | Updated Date 11/2/2025 |
52 Weeks Range 0.92 - 2.75 | Updated Date 11/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -341.46% |
Management Effectiveness
Return on Assets (TTM) -59.15% | Return on Equity (TTM) -192.87% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 9065408 | Price to Sales(TTM) 2.9 |
Enterprise Value 9065408 | Price to Sales(TTM) 2.9 | ||
Enterprise Value to Revenue 2.97 | Enterprise Value to EBITDA -0.91 | Shares Outstanding 9077326 | Shares Floating 8219246 |
Shares Outstanding 9077326 | Shares Floating 8219246 | ||
Percent Insiders 1.04 | Percent Institutions 7.8 |
Upturn AI SWOT
Intelligent Bio Solutions Inc.
Company Overview
History and Background
Intelligent Bio Solutions Inc. (IBS) focuses on developing and commercializing rapid, point-of-care diagnostics and drug testing solutions. Founded to address the growing need for fast and accurate screening, IBS aims to revolutionize testing across various industries.
Core Business Areas
- Drug Testing Solutions: Develops and commercializes rapid, non-invasive drug screening devices using oral fluid samples.
- Point-of-Care Diagnostics: Developing platforms for other medical diagnostics beyond drug screening, aiming for quick results at the point of care.
Leadership and Structure
The company has a management team focusing on technology, sales, and operations. The organizational structure is typical for a publicly traded company, with a board of directors and executive leadership overseeing various departments.
Top Products and Market Share
Key Offerings
- Intelligent Bio Solutions Drug Screening Devices: Rapid, non-invasive drug screening using oral fluid. Market share data is not readily available. Competitors include Abbott, Roche, and OraSure Technologies.
Market Dynamics
Industry Overview
The drug testing market is experiencing growth driven by increasing regulatory requirements and the opioid crisis. Point-of-care diagnostics are also expanding, providing faster and more accessible testing options.
Positioning
Intelligent Bio Solutions focuses on non-invasive, rapid testing, potentially offering a competitive advantage in convenience and ease of use.
Total Addressable Market (TAM)
The global drug testing market is estimated at billions of USD annually. IBS is positioned to capture a portion of this market with its innovative testing solutions.
Upturn SWOT Analysis
Strengths
- Non-invasive testing technology
- Rapid results
- Point-of-care applications
Weaknesses
- Limited market share
- Dependent on regulatory approvals
- Requires further validation through clinical trials
Opportunities
- Expanding drug testing market
- Increasing demand for point-of-care diagnostics
- Potential for partnerships and collaborations
Threats
- Competition from established players
- Regulatory hurdles
- Technological advancements by competitors
Competitors and Market Share
Key Competitors
- Abbott (ABT)
- Roche Holding AG (ROG.SW)
- OraSure Technologies (OSUR)
Competitive Landscape
IBS faces significant competition from established players with larger market shares and broader product portfolios. Its competitive advantage lies in its non-invasive technology and focus on rapid testing.
Growth Trajectory and Initiatives
Historical Growth: Growth is expected, dependent on regulatory approvals, partnerships, and market acceptance.
Future Projections: Analyst estimates are not readily available due to the speculative nature of the business. Future growth is tied to product approvals and market penetration.
Recent Initiatives: Focus on regulatory approvals, product development, and establishing partnerships.
Summary
Intelligent Bio Solutions is an early-stage company focusing on innovative drug screening technology. The company's success depends on receiving regulatory approvals, forming strategic partnerships, and effectively marketing its products. Its non-invasive approach could provide a competitive edge, but it must overcome challenges related to gaining market share. The company requires a significant amount of money to continue operations and needs to be very strategic.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Industry reports
Disclaimers:
The information provided is for informational purposes only and should not be considered as financial advice. Market share data may be estimated. Information might be outdated. Consult a financial professional before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Intelligent Bio Solutions Inc.
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2020-12-23 | President & CEO Mr. Harry Simeonidis | ||
Sector Healthcare | Industry Medical Devices | Full time employees 53 | Website https://ibs.inc |
Full time employees 53 | Website https://ibs.inc | ||
Intelligent Bio Solutions Inc., a medical technology company, focused on developing and delivering non-invasive testing, and screening solutions in Asia Pacific, the United States, the United Kingdom, and internationally. The company operates intelligent fingerprinting drug screening system, a platform to analyze fingerprint sweat analysis to detect drugs abuse; and biosensor platform. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. Intelligent Bio Solutions Inc. was incorporated in 2016 and is headquartered in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.